

About Valbenazine

What is valbenazine?

- Approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®
- Valbenazine is being studied for the treatment of chorea associated with Huntington disease (HD).

Are there any side effects from valbenazine?

The most commonly-reported side effects associated with valbenazine administration include*:

- Drowsiness
- Tiredness
- Sedation (feeling calm, relaxed, or sleepy)

**For additional information, speak with the clinical investigator at one of the participating HSG sites.*

"We believe the mechanism of valbenazine is highly relevant for treatment of chorea in HD. Valbenazine has been shown to improve involuntary movements in patients with tardive dyskinesia, and we are excited that we are now also able to investigate this effect in HD."

*-Dietrich Haubenberger, MD
Medical Director, Neurocrine Biosciences, Inc*

To Learn More

How can someone participate in KINECT-HD?

If you or someone you know is interested in taking part in **KINECT-HD**, please contact HSG to find a site nearest you. Study center personnel will determine eligibility to participate in the **KINECT-HD** study.



KINECT HD

A Clinical Study
for Huntington Disease Chorea

NOW ENROLLING!

Participants are needed for this clinical trial of valbenazine, an investigational study drug for the treatment of Huntington Disease (HD) chorea.

Call: Toll-Free (U.S. and Canada): 800-487-7671

Email: info@hsglimited.org

Visit: <http://www.KINECT-HD.org/>

KINECT-HD is being conducted by the Huntington Study Group (HSG), on behalf of Neurocrine Biosciences, Inc. as the clinical trial sponsor.

KINECT HD



neurocrine
BIOSCIENCES



HUNTINGTON
STUDY GROUP
seeking treatments that make a difference



neurocrine
BIOSCIENCES



HUNTINGTON
STUDY GROUP
seeking treatments that make a difference

About KINECT-HD

What is the KINECT-HD Study?

The use of valbenazine to treat chorea associated with HD is not approved by the U.S. Food and Drug Administration (FDA).

The purpose of this research study is:

- To evaluate the effectiveness of valbenazine to reduce chorea associated with Huntington disease (HD)
- To evaluate the safety and tolerability of valbenazine (valbenazine tosylate, NBI-98854)

What is a clinical trial?

- A clinical trial is a type of research study.
- Scientists conduct clinical trials to learn information about a disease or condition.
- Clinical trials attempt to identify potential treatments for a disease or condition.
- Clinical trials are designed to learn if investigational drugs are safe, tolerable, and effective.



Eligibility for KINECT-HD

Who can participate?

KINECT-HD will enroll approximately 120 participants into the study who must meet several criteria, including:

- Male or female, ages 18 to 75 years
- Diagnosis of motor manifest HD
- Have sufficient chorea symptoms to meet study protocol criteria
- Willing and able to comply with the study instructions



Where is the clinical study taking place?

- KINECT-HD is being conducted in approximately 55 HSG study centers in the United States and Canada.



Visit the HSG's KINECT-HD website for specific locations

Participant Experience

How long is the study?

Participation in this study consists of 9 total study visits that will last a total of 18 weeks:

- Includes up to 4 weeks of screening
- Have up to 12 weeks of study drug dosing
- Requires a final study visit 2 weeks after the last dose of the study drug (valbenazine) or placebo

How is the study drug administered?

- You will take the study drug at home, on your own (or in the presence of your caregiver, if applicable) once daily.

Will I receive study drug (valbenazine) or placebo?

- KINECT-HD participants will be randomly selected (like the flip of a coin) to receive the study drug (valbenazine) or placebo.

"We are excited about a symptomatic treatment trial for HD related chorea. We hope this trial, if successful, will provide patients and clinicians with another effective option to address HD motor symptoms."

*-Erin Furr-Stimming, MD
HSG Principal Investigator, KINECT-HD*